Clinical care and other categories posters: Insulin: Actions, metabolism and therapy

Clinical care and other categories posters: Insulin: Actions, metabolism and therapy P390Evaluation of biosimilar insulin use: Perception and experience (INSPIRE)R DONNELLY, M Burke, L Haire, S Baxter and W MundayDiabetes Team, South Eastern Health & Social Care Trust, Dundonald, UKBackground: Abasaglar, the first UK licensed biosimilar insulin glargine, has been shown not to have any clinically significant differences from Lantus in terms of quality, safety and efficacy. Future diabetes management will see an expansion in the availability of biosimilar insulin and has the potential to offer the National Health Service considerable cost savings. Patient and clinical staff perspectives may be an important determinant in the success or failure of this exciting development in diabetes care.Aims: The aim of this evaluation was to explore perceptions of Abasaglar prescribing within the South Eastern Health and Social Care Trust diabetes team. The evaluation also sought to explore the experiences of patients prescribed Abasaglar compared to those prescribed Lantus.Methods: Clinical staff were made aware of the rationale for the service evaluation. Education sessions were provided and staff were invited to consider prescribing Abasaglar according to current National Institute for Health and Care Excellence (NICE) guidelines. Questionnaires were circulated at baseline and nine months. Perspectives assessed; staff insight, viewpoint, attitudes and barriers to prescribing biosimilar http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetic Medicine Wiley

Clinical care and other categories posters: Insulin: Actions, metabolism and therapy

Loading next page...
 
/lp/wiley/clinical-care-and-other-categories-posters-insulin-actions-metabolism-nNg6VkhG06
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Diabetic Medicine © 2018 Diabetes UK
ISSN
0742-3071
eISSN
1464-5491
D.O.I.
10.1111/dme.41_13571
Publisher site
See Article on Publisher Site

Abstract

P390Evaluation of biosimilar insulin use: Perception and experience (INSPIRE)R DONNELLY, M Burke, L Haire, S Baxter and W MundayDiabetes Team, South Eastern Health & Social Care Trust, Dundonald, UKBackground: Abasaglar, the first UK licensed biosimilar insulin glargine, has been shown not to have any clinically significant differences from Lantus in terms of quality, safety and efficacy. Future diabetes management will see an expansion in the availability of biosimilar insulin and has the potential to offer the National Health Service considerable cost savings. Patient and clinical staff perspectives may be an important determinant in the success or failure of this exciting development in diabetes care.Aims: The aim of this evaluation was to explore perceptions of Abasaglar prescribing within the South Eastern Health and Social Care Trust diabetes team. The evaluation also sought to explore the experiences of patients prescribed Abasaglar compared to those prescribed Lantus.Methods: Clinical staff were made aware of the rationale for the service evaluation. Education sessions were provided and staff were invited to consider prescribing Abasaglar according to current National Institute for Health and Care Excellence (NICE) guidelines. Questionnaires were circulated at baseline and nine months. Perspectives assessed; staff insight, viewpoint, attitudes and barriers to prescribing biosimilar

Journal

Diabetic MedicineWiley

Published: Jan 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off